Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD

A Prospective Multicenter Randomized Controlled Study of Adaptive Therapy in Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD

It is a prospective, multicenter, randomized controlled trial to investigate the predictive value of MRD on adjuvant therapy. Stage IA2-II resected NSCLC patients will undergo two-round MRD tests after surgery, first in 3-7 days and second in 1 month after surgery. And patients who confirm two-round landmark undetectable MRD will be enrolled and randomly assigned to the conventional treatment group or the adaptive therapy group . Patients in the the adaptive therapy group will undergo closely MRD and imaging monitoring without adjuvant therapy if the MRD was negative.

Inclusion Criteria:

• Stage IA2-II non-small cell cancer patients who after complete resection.
• Two-round MRD tests confirm landmark undetectable MRD
• Expected survival ≥24 months
• ECOG PS 0-1
• Willing to accept MRD monitoring every 3 months for a total of 2 years after surgery

Exclusion Criteria:

• Patients who had previously undergone radiotherapy or chemotherapy or any other anti-tumor therapy
• Patients with a history of other malignancies in the past 5 years
• Any unstable systemic disease (eg, active infection, high-risk hypertension, unstable angina, congestive heart failure, etc.) or other conditions that investigators considered would limit the ability of the patient to participate in the study